The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.128.6.778

The authors studied seven children with either pavor nocturnus or somnambulism, or both, in an attempt to find a method of treating these sleep disorders. Each child received imipramine orally at bedtime for a minimum of eight weeks. In all seven patients a complete cessation of symptoms resulted. Although the drug seems to be an effective treatment for these disorders, its mechanism of action is not yet known.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.